Skip to content
JJJ898989

Drawing based on the label description. No photo yet.

“Amlodipine, Valsartan and Hydrochlorothiazide Tablets USP, 5 mg/160 mg/25 mg - Yellow colored, ovaloid, beveled edge, biconvex film-coated tablet, debossed with 'J' on one side and '89' on the other side”

J 89 pill

Pill with imprint J 89 is yellow, oval, 18 mm and has been identified as Amlodipine, Valsartan and Hydrochlorothiazide 5 mg / 160 mg / 25 mg. It is used for high blood pressure. It is supplied by Aurobindo Pharma Limited.

Amlodipine, Valsartan and Hydrochlorothiazide 5 mg / 160 mg / 25 mg

Imprint
J 89
Strength
Amlodipine 5 mg / Valsartan 160 mg / Hydrochlorothiazide 25 mg
Used for
High blood pressure
Color
Yellow
Shape
Oval
Size
18 mm
Score
No score line
Form
Tablet, film coated
Manufacturer
Aurobindo Pharma Limited
Drug class
Thiazide diuretic (water pill)
NDC
65862-835, 65862-835-30, 65862-835-90, 65862-835-05

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Amlodipine Valsartan and Hydrochlorothiazide pills and guides

What is Amlodipine Valsartan and Hydrochlorothiazide used for?

Amlodipine Valsartan and Hydrochlorothiazide is used for high blood pressure.

Medicine type
Thiazide diuretic (water pill)
Official uses from the US prescribing label

Exforge HCT (amlodipine, valsartan, and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the angiotensin II receptor blocker (ARB) class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Exforge HCT.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Limitations of Use

Exforge HCT is not indicated for the initial therapy of hypertension.

From the FDA-approved label on DailyMed (published Dec 15, 2025).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows J and the other side shows 89.
  • It is yellow, oval, 18 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Amlodipine Besylate, Valsartan, Hydrochlorothiazide

Inactive: Silicon Dioxide, Hypromellose 2910 (6 Mpa.s), Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol 4000, Povidone K30, Starch, Corn, Sodium Starch Glycolate Type A Potato, Talc, Titanium Dioxide, Ferric Oxide Yellow

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Amlodipine Valsartan and Hydrochlorothiazide pills